PDSB surged +51.60% during regular market hours to roughly $0.60, extending Monday's rally. Primary catalyst: the initial closing of a PIPE financing of up to $22.3M led by Nant Capital (Dr. Patrick Soon-Shiong), raising ~$11.3M in its first tranche.

DMRA dropped roughly -10.85% to about $25.31 in regular trading, down $3.08 from the prior session's $28.39 close. The move occurred during normal market hours, extending a volatile stretch after an ~800%+ one-year run.

CTMX is down roughly -10.63% intraday during regular trading, sliding to about $2.86 from a prior close of $3.20 on elevated volume. The decline extends a week-long slide, with shares closing lower each session since September 8.

ASND fell -11.92% to roughly $233.34 during regular trading hours, down from a prior close of $264.92. The selloff follows the company's Monday evening decision to reclaim full rights to its TransCon metabolic and cardiovascular (obesity) programs from Novo Nordisk.

The selected price target is $20 per share , roughly double the stock's recent closing price near $9.75. The strongest bullish factor is a clinical catalyst pipeline for SAT-3247, including the TRAILHEAD study in adults and the Phase 2 BASECAMP readout expected in late 2026.

ADAG trades near $3.40, down roughly 9% over the trailing month and range-bound between about $3.20 and $4.25 since mid-August 2026. Six-month 2026 results reported in August showed cash and equivalents of about $127.9 million and a runway extended into late 2028.

IMRX fell roughly 15.8% over the last 30 days, from $5.07 on August 12, 2026, to $4.27 at the September 11, 2026 close. The decline unwound a mid-August rally that had carried shares to a peak near $5.33 on August 19, 2026.

HALO trades near $107, up roughly 6.5% over the trailing 30 days and holding close to its 52-week high of $111.15. Second-quarter results beat expectations, with total revenue up 48% and royalty revenue up 50% year over year.

Candel Therapeutics (CADL) fell -8.38% to about $10.38 in regular-session trading, extending a two-day slide after a run-up to its 52-week high near $14. The drop continued a profit-taking pullback following the company's Sept. 10 Cantor conference appearance, where management flagged an "extremely tight" manufacturing and regulatory timeline ahead of the planned Q4 BLA filing for lead candidate aglatimagene (CAN-2409).

ALMS is trading down -6.16% to $9.29 during the regular session, versus a prior close of $9.90. Primary catalyst: Wells Fargo slashed its price target to $25 from $51 while keeping an Overweight rating, citing reduced odds for the lupus program.

BHVN dropped -15.93% to $12.61 during regular trading, after the FDA disclosed a partial clinical hold on its BHV-7000 epilepsy program. The decline began premarket as Biohaven revealed the FDA paused new patient enrollment in the Phase 2/3 trial after rodent studies flagged a potentially toxic drug metabolite.

ATNM is up +8.94% intraday, trading near $1.34 versus a prior close of $1.23, with the move occurring during regular market hours. The gain extends a multi-day rally following positive Phase 3 SIERRA data for Iomab-B in relapsed/refractory AML, which met its primary endpoint of durable complete remission.

The central question is whether Summit Therapeutics (SMMT) can reclaim the $30 level, roughly 71% above its recent price near $17.54. The strongest bullish case rests on ivonescimab, a Phase III oncology drug candidate with a pivotal lung cancer readout expected in the second half of 2026.

TYRA fell about -28.8% to $19.03 from a prior close of $26.73, with the slide starting in premarket trading (down roughly -31% pre-open). The move came after initial Phase 2 SURF302 data for dabogratinib in FGFR3-mutated low-grade intermediate-risk non-muscle invasive bladder cancer.

ROIV surged +15.77% to roughly $40.44, extending a sharp premarket rally that pushed shares above their prior 52-week high of $37.97. The move was driven by a positive Phase 2 PHocus study of mosliciguat in pulmonary hypertension with interstitial lung disease (PH-ILD), meeting primary and secondary endpoints.

BridgeBio Pharma shares declined roughly 10.2% over the trailing 30 days, falling from a closing price of $84.48 on August 7, 2026, to about $75.89. Despite the recent pullback, BBIO remains up approximately 12.6% over the trailing quarter, reflecting a broader, multi-month uptrend.

BEAM is down roughly -13.96% intraday, trading near $25.52 versus the prior session's $29.66 close, with the selloff occurring during regular market hours. The move follows Beam's late-breaking BEAM-302 Phase 1/2 data presentation for alpha-1 antitrypsin deficiency (AATD) at the ERS Congress 2026, alongside a 7:00 a.m. ET investor webcast.

DYN tumbled -23.72% to about $18.52 from a prior close of $24.28, with the selloff starting in premarket trading and persisting into the regular session. The catalyst was rival Novartis reporting that its del-desiran Phase 3 trial in myotonic dystrophy type 1 (DM1) missed its primary endpoint, pressuring Dyne's own DM1 program (z-basivarsen).

Insmed shares trade near $126, roughly 3%–4% lower over the trailing 30 days following a sharp post-earnings surge in early August. BRINSUPRI (brensocatib), the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB), remains the company's central growth engine.

Selected price target: $1.00, roughly 49% above the latest price near $0.67, representing both a round-number milestone and Nasdaq's minimum bid price threshold. Strongest bullish factors: FDA approval of LYTENAVA for wet age-related macular degeneration (AMD), a planned U.S. commercial launch, and a "Buy"-leaning analyst consensus with targets well above $1.